The FDA has expanded the approval of Odactra to include treatment of house dust mite-induced allergic rhinitis in pediatric patients aged 5 to 11 years.

Allergy sufferers in some parts of the country face significant challenges in accessing care, as one group warns patients are ...

In a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy human airways are at higher risk for dehydration and inflammation when ...

Spring allergy season is expected to worsen in 2025. Longer growing seasons due to climate change have caused seasonal ...

Xyzal (levocetirizine) and Zyrtec (cetirizine) are over-the-counter (OTC) allergy medications. Learn about their key ...

Rhinitis and pharmacological agents used for treatment are considered factors that could alter the rate and extent of absorption of drugs administered by the nasal route. The purpose of this study ...

China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis.

The U.S. Food and Drug Administration has expanded its indication of ALK's Odactra, a house dust mite allergen tablet, for ...

Ocular surface disease symptoms in individuals with comorbid atopic dermatitis are more common and severe, and self-rated vision is worse.

Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent (application #17/466,142) relating to the ...